Investigational drug · Phase 2
PKN605
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Atrial Fibrillation.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "PKN605"
First trial start
2025
Oct 28, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PKN605", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atrial Fibrillation
Approved drugs for the same conditions: Atrial fibrillation · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "PKN605" as an intervention, largest first.
- A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial FibrillationPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07217067 · 165 participants (planned) · Start Oct 28, 2025 · Primary completion Sep 9, 2027
Drug: PKN605 · For: Atrial Fibrillation
Sites: Tupelo, Mississippi; Camden, New Jersey; New York, New York · 40 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT07797322 · 40 participants (planned) · Start Oct 1, 2026 · Primary completion Mar 1, 2027
Drug: PKN605 · For: Participants With Moderate and Severe Renal Impairment and Healthy Participants
Sites: Miami, Florida; Orlando, Florida; Tampa, Florida
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Atrial Fibrillation
- MilvexianJNJ-70033093, BMS-986177Phase 33 trials
Johnson & Johnson (Janssen) · Ischemic Stroke; Ischemic Attack, Transient, Atrial Fibrillation, Acute Coronary Syndrome
- BAY 3670549Phase 21 trial
Bayer · Atrial Fibrillation
- HBI-3000sulcardine sulfatePhase 21 trial
HUYABIO International, LLC. · Atrial Fibrillation
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.